publication date: Jan. 9, 2015
Duke University would have avoided embarrassment, a misconduct investigation and a lawsuit, had its top administrators paid closer attention to a thoughtful report by a medical student who saw problems in the lab of the disgraced scientist Anil Potti.
Documents obtained by The Cancer Letter show that Duke’s deans were warned about Potti’s misconduct in late March and early April 2008, at the time when clinical trials of the now discredited Duke genomic technology were getting started.
The three-page document was penned by Bradford Perez, then a third-year medical student and a Howard Hughes Medical Institute scholar.
Instead of rewarding the student’s brilliance with a plaque and a potted plant, Potti’s collaborator and protector, Joseph Nevins—aided by a phalanx of Duke deans—pressured the young man to refrain from making a final complaint and reporting the matter to HHMI.
The Med Student’s Memo
Joseph McLaughlin, 66, Cancer Epidemiologist
Joseph McLaughlin, an internationally recognized epidemiologist who made numerous contributions towards increasing understanding of the causes of cancer, died unexpectedly Dec. 10, 2014.
He directed key research in the United States and abroad clarifying the roles of tobacco, obesity, diet, occupation and other factors in the etiology of several cancers, especially kidney cancer, for which he was considered among the world’s experts. He led some of the largest studies exploring the etiology of renal cell and renal pelvis cancers, quantifying levels of risk associated with multiple lifestyle and environmental factors.
Anthony Murgo, of the FDA Office of Hematology and Oncology Products
Anthony (Tony) J. Murgo, died Dec. 17, 2014 after a courageous year-long battle with cancer. He was a passionate research physician with a kind bedside manner.
Murgo was a dedicated federal employee for 25 years, serving in multiple capacities at FDA and NCI. As the associate director of regulatory science of the FDA’s Office of Hematology and Oncology Products, Murgo was the liaison between that office and NCI’s Cancer Therapy Evaluation Program. Within OHOP, Murgo also served as a medical reviewer, a team leader and a division director for Division of Oncology Products 1.
Drugs and Targets
- Accelerated Approval Granted to Opdivo in Metastatic Melanoma
- FDA approved a supplemental biologics license application for Gazyva
- FDA approved an updated version of MarginProbe
- FDA granted Fast Track designation to SGX301
- Polaris Group’s lead product candidate, ADI-PEG 20 receives US and EU orphan designations
- Amgen and Kite Pharma entered into a strategic research collaboration
- Taiho Oncology Inc. submits NDA for TAS-102
Donald Trump named CEO of Inova Cancer Care and Research Institute
Dario Altieri named CEO of The Wistar Institute
Sharmila Makhija named chair of the Department of Obstetrics & Gynecology and Women’s Health at Albert Einstein College of Medicine
Nipun Merchant joins Sylvester Comprehensive Cancer Center
St. Jude receives $2 million pledge from InfinityQS International Inc.
NCI Director Harold Varmus addresses NCI staff and grantees with an outlook on the new year